Moderna Secures Landmark mRNA Flu Vaccine Approval, But a Split Decision Creates Post-Marketing Risk for the Key Senior Population

FDA Approves Moderna's mFLUVISA After Regulatory Hurdles

Moderna has received FDA approval for its mRNA-based flu vaccine, mFLUVISA, marking the first mRNA flu shot in the U.S. The vaccine secured traditional approval for individuals aged 50-64 and accelerated approval for those 65 and older. This decision follows a challenging regulatory path, including an initial refusal-to-file letter from the FDA, which was later reversed. Moderna anticipates making mFLUVISA available for the 2026-2027 respiratory virus season, with analysts projecting significant sales growth for the company beyond its COVID-reliant revenues, particularly in 2027-28.

• The FDA granted mFLUVISA traditional approval for preventing seasonal influenza in adults aged 50 through 64 years, recognizing its established efficacy and safety profile. For individuals 65 years and older, the vaccine received accelerated approval, indicating a need for a post-marketing trial to confirm clinical benefit in this older population.
• Moderna's mFLUVISA faced an initial refusal-to-file letter from the FDA in February, citing concerns about the pivotal study's control group. However, the agency later accepted a revised submission after Moderna disputed the characterization, leading to a unanimous backing for approval by the Vaccines and Related Biological Products Advisory Committee in June.
• Clinical trial results, released in June 2025, showed that mFLUVISA was 26.6% more effective than a commercial standard-dose flu vaccine in preventing influenza among adults 50 years and older. This efficacy data underpinned the FDA's decision, supporting the vaccine's potential to offer improved protection against seasonal flu.
• Moderna expects to launch mFLUVISA in the coming weeks, ahead of the 2026-2027 respiratory virus season in the U.S. Analysts view this approval as a crucial new commercial growth driver for Moderna, diversifying its revenue streams beyond COVID-19 vaccines, with sales anticipated to significantly contribute to the company's financials starting in 2027.

mFLUVISA: A New Era for Seasonal Influenza Prevention

The seasonal influenza treatment landscape, while still anchored by neuraminidase inhibitors (NAIs) like oseltamivir, has significantly evolved with the increasing clinical evaluation of the endonuclease inhibitor baloxavir marboxil. Early antiviral initiation, preferably within 48 hours of symptom onset, remains a cornerstone of therapy for both drug classes. Recent comparative data highlight baloxavir's advantages in specific contexts. A 2022-2023 study in Japan demonstrated superior viral clearance with baloxavir versus oseltamivir in outpatients with influenza A(H3N2), showing 0% viral detection on day 10 compared to 16.7% for the NAI. Furthermore, a 2024 household transmission study found that treating index cases with baloxavir resulted in a 41.8% greater relative reduction in the secondary attack rate among household contacts compared to oseltamivir. This clinical evidence is supported by a 2026 cost-effectiveness analysis which concluded that baloxavir is a dominant strategy over oseltamivir in both high-risk and otherwise healthy populations, yielding lower costs and higher quality-adjusted life years (QALYs).

Evidence from trials in specific patient populations and large-scale meta-analyses provides a more nuanced view of the comparative efficacy of available agents. In kidney transplant recipients, baloxavir demonstrated significantly faster fever resolution than oseltamivir when initiated within 48 hours and notable symptom alleviation when started after 48 hours. Conversely, a 2024 study in hospitalized, immunocompromised adults found no significant differences between the two drugs in clinical outcomes like time to resolution of hypoxia or 30-day mortality. A 2025 network meta-analysis of 34 treatments revealed that while oseltamivir (300 mg/day) provided the largest reduction in time to fever alleviation, baloxavir (40 mg/day) was most effective in reducing time to symptom alleviation, and intravenous peramivir (300 mg/day) was superior for hastening the resumption of usual activities. These findings underscore that treatment choice may be influenced by the specific patient population and desired clinical endpoint.

Looking ahead, the landscape is shaped by the challenge of antiviral resistance and the development of novel therapeutic strategies. Treatment-emergent resistance occurs with both NAIs and baloxavir, with I38T/M substitutions in the polymerase acidic protein (PA) observed in up to 5.6% of baloxavir-treated patients in one study, though without a major impact on clinical recovery. While current evidence does not support routine use of combination therapy, preclinical research shows significant promise. For instance, combining baloxavir with the JAK inhibitor oclacitinib has been shown to extend the therapeutic window, a critical factor given baloxavir’s efficacy declines sharply if not administered early. The pipeline also includes monoclonal antibodies (e.g., MEDI8852, CR9114) and agents targeting novel viral components, such as the influenza nucleoprotein, indicating a continued evolution toward more robust and resistance-proof treatment options.

Understanding mFLUVISA's Efficacy and Safety Data

Recent trials spanning vaccines, antivirals, and adaptive platform designs continue to expand the seasonal influenza evidence base, with particular momentum around mRNA-based vaccine candidates and optimized antiviral timing strategies. The following studies represent key efficacy and safety findings from 2023 through projected 2026 publications, spanning diverse populations including chronic disease patients, pediatric cohorts, older adults, and those with autoimmune disease.

• NUDGE-FLU-CHRONIC Trial (2023-2024 season): This nationwide randomized trial tested six electronic nudge letters to boost influenza vaccination uptake among 299,881 citizens aged 18-64 with chronic disease. Uptake was higher with any nudge letter versus usual care, with a stronger effect in those with atrial fibrillation (45.9% vs. 31.1%; +14.8 percentage points; RR 1.48) than those without (39.1% vs. 27.7%; +11.4 percentage points; RR 1.41). Safety outcomes were not reported.

• GSK Quadrivalent IIV4 Safety Study (2023/24 season): A multicenter, non-interventional study across Belgium, Germany, and Spain (997 participants) assessed GSK's quadrivalent influenza vaccine. AEs occurred in 42.6% post-Dose 1 (mainly injection site pain, fatigue, headache) and 28.6% post-Dose 2 (mainly injection site pain); the profile was consistent across age and risk groups, with no serious AEs or new safety signals identified.

• California Influenza Vaccine Effectiveness Study (2024-2025 season): This case-control analysis of over 1.1 million tested individuals estimated vaccine effectiveness at 40% (95% CI, 39%-41%). Among 801 influenza-associated deaths, vaccination in adults ≥65 years was associated with lower odds of death (adjusted OR 0.71; 95% CI, 0.60-0.84). Safety data were not reported.

• Trivalent Inactivated Influenza Vaccine Study in China (2022-2024): This prospective observational study in older adults compared consecutive two-season vaccination against single-season vaccination. Consecutive vaccinees had higher pre-vaccination GMTs and seroprotection for H1N1/H3N2, but no intergroup differences emerged at 30/90/180 days post-vaccination; at 30 days, consecutive vaccinees showed lower fold-rises and seroconversion for H1N1/H3N2, suggesting comparable serological response regardless of prior vaccination history.

• Brazilian SIVEP-Gripe Database Study (2024): This retrospective cohort of 15,995 hospitalized influenza cases (12.1% case fatality rate) found influenza vaccination (OR 0.77) and oseltamivir use (OR 0.81) were both protective against mortality; COVID-19 booster vaccination was independently associated with reduced mortality (OR 0.90; 95% CI 0.84-0.97). The model showed good discrimination (AUC=0.81).

• Oseltamivir Timing Study in Hospitalized Children (2020-2023): In 280 pediatric patients (1 month-14 years) with confirmed influenza, early oseltamivir (within 48 hours) significantly shortened hospital stay (3.28 ± 1.46 vs. 3.95 ± 2.26 days; P=0.007) and reduced incidence of pneumonia, otitis media, and asthma exacerbation (P<0.05 for all) versus late treatment.

• Baloxavir Marboxil in Pediatric Populations (Meta-analysis, 2026): This meta-analysis of 12 studies (4,586 patients, ages 1 month-14 years) found baloxavir accelerated fever resolution versus neuraminidase inhibitors (MD = -13.16 hours; P<0.0001), with additional benefit in influenza A infections (MD = -9.40 hours symptom time; MD = -8.50 hours to symptom alleviation). Safety data showed a 59% reduction in drug-related AEs versus oseltamivir (OR 0.41; P<0.001), with comparable overall AE rates (OR 0.85; P=0.14); continued monitoring for baloxavir-resistant mutations (e.g., PA/I38T) was recommended.

• mRNA-1010 Efficacy Trial in Adults ≥50 Years (2026): Among 40,703 participants, mRNA-1010 demonstrated 26.6% relative vaccine efficacy (95% CI: 16.7-35.4) against RT-PCR-confirmed influenza-like illness versus standard-dose comparator, meeting noninferiority and superiority criteria. Solicited reactions (injection-site pain, fatigue, headache, myalgia) were more frequent with mRNA-1010 but predominantly mild-to-moderate and transient; serious AE rates were similar between arms (2.2% vs. 1.9%).

• mRNA Vaccine Safety Meta-Analysis (2026): Pooling seven RCTs (23,754 intervention vs. 22,806 comparator participants, all US-based), this analysis found no increased risk of SAEs (RR=0.90; P=.56) or adverse events of special interest (RR=0.76; P=.35), with low-to-moderate heterogeneity for SAEs and none for AESIs; risk-of-bias assessment was low across all domains.

• General Influenza Vaccine Efficacy Meta-Analysis (2025): Across 26 RCTs (104,931 participants), pooled vaccine efficacy against laboratory-confirmed influenza was 48.48% (95% CI: 41.9-54.29), with inactivated vaccines showing the highest efficacy (54.70%) and H1N1 protection the strongest by strain (59.38%). Seroconversion and seroprotection rates showed moderate correlation with viral attack rates.

• Vaccine Effectiveness in Older Adults - China Study (2026): This test-negative case-control study of 3,214 adults ≥60 years in Jiaxing (2022-2025) reported overall adjusted VE of 42.5% (95% CI: 31.2-51.9), peaking in the 2024-2025 season (47.2%) and against H1N1 (42.4%). VE was significantly higher among females, those without underlying disease, and within 90 days post-vaccination.

• Platform Trials (REMAP-CAP and RECOVERY, 2025): These adaptive platform trials, building on their COVID-19 track record, are now evaluating antiviral and immunomodulatory therapies for severe influenza, enabling simultaneous multi-intervention assessment and rapid adaptation to emerging data.

mRNA Flu Vaccine: A New Era for Influenza Protection

The FDA's approval of Moderna's mFLUVISA marks a significant inflection point in the fight against seasonal influenza, ushering in the era of mRNA-based flu vaccines. This landmark decision not only validates the mRNA platform's capabilities beyond its pivotal role in the COVID-19 pandemic but also signals a potential paradigm shift in how influenza vaccines are developed and deployed. Research indicates that mRNA technology offers distinct advantages, including the potential for rapid strain updates, the development of high-valent formulations, and the ability to target conserved antigens, which could lead to broader and more durable protection against the constantly evolving influenza virus.

For Moderna, this approval is a strategic triumph, providing a crucial avenue for revenue diversification and reducing its reliance on COVID-19 vaccine sales. The accelerated approval for individuals aged 65 and older is particularly impactful, as this demographic often experiences suboptimal immune responses to traditional flu vaccines, as studies have shown. mFLUVISA could therefore address a significant unmet need, offering improved protection for a high-risk population and reshaping the competitive landscape.

However, several considerations remain. While the mRNA platform promises rapid adaptability, the persistent challenge of influenza's antigenic drift and the complexities of lineage changes, especially for influenza B, will require continuous evaluation of mFLUVISA's real-world effectiveness. Studies have highlighted how changes in vaccine composition can affect immune responses, particularly in previously primed individuals. Furthermore, the initial regulatory hurdles faced by mFLUVISA, though overcome, underscore the importance of robust data and transparent communication to build and maintain public trust in this novel vaccine technology. The long-term impact on public health will depend on sustained efficacy across diverse populations and against future circulating strains, potentially paving the way for a truly universal influenza vaccine.